Wedgewood Pharmacy has officially added molnupiravir to its formulary, offering a new option for the treatment of Feline Infectious Peritonitis (FIP). Originally developed to treat viral infections in humans, including COVID-19, molnupiravir is now recognized as a promising therapeutic option…
Blue Cross and Blue Shield of Alabama is dedicated to ensuring its members receive high-quality, affordable care through cost-effective healthcare providers. Starting December 1, 2024, Labcorp, a leader in comprehensive laboratory services, will be the exclusive national laboratory for Blue…
Zoetis Inc., the leading global animal health company, is set to launch its new Vetscan OptiCell™ hematology analyzer, a cutting-edge diagnostic tool that combines cartridge-based technology with AI-powered capabilities for advanced Complete Blood Count (CBC) analysis. Expected to debut in…
Massive Bio Launches Patient Connect: A Revolutionary Platform for Global Cancer Clinical Trial Access Massive Bio, a global frontrunner in AI-driven cancer clinical trial enrollment, has unveiled Patient Connect, a groundbreaking and free portal designed to guide cancer patients through…
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, has announced new findings from a study using its Cellworks Platform to predict homologous recombination deficiency (HRD) and the effectiveness of PARP inhibitors (PARPi) across real-world…
Novotech, a global contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Executive President of Asia Pacific (APAC), effective September 1, 2024. This move reflects Novotech’s dedication to expanding its global reach and enhancing its operational…
Results from the DESTINY-Breast12 Phase IIIb/IV trial reveal that Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, including those with brain metastases who had undergone no more than two previous lines…
Pfizer Inc. (NYSE: PFE) continues to highlight groundbreaking research and next-generation therapies from its comprehensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, held from September 13-17 in Barcelona. The company will present data from over…
Eli Lilly and Company (NYSE: LLY) today released detailed findings from the QWINT-5 phase 3 trial, which compared once-weekly insulin efsitora alfa (efsitora) to daily insulin degludec in adults with type 1 diabetes. These patients required both daily basal insulin…
Oisín Biotechnologies, a privately held company dedicated to addressing age-related diseases, has announced the publication of preclinical data from its follistatin (FST) gene therapy program. The findings, detailed in the article “Safe and Effective Delivery of DNA and RNA Using…
Novotech, a leading global full-service Contract Research Organization (CRO), has been honored with the 2024 Global Company of the Year Award by Frost & Sullivan. This prestigious accolade highlights Novotech’s dedication to enhancing clinical development for biotech firms through cutting-edge…
CorFlow Therapeutics AG has secured €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners. The funding round also saw participation from 415 Capital, CorFlow’s initial investor and largest shareholder, alongside Merieux Equity Partners, Laerdal Million Lives…
